Seres Therapeutics

Member for

2 years 7 months
HCP ID number type
CRM
Notifications
Off
Profile Complete
Off
Submitted by Olha.Tkachiv@u… on
We have an exclusive agreement with Seres to jointly commercialize SER-109, Seres' investigational oral microbiome therapeutic for recurrent Clostridium difficilie infection. If approved, it would be the first-ever FDA-approved microbiome therapeutic. The agreement to co-commercialize SER-109 in the US and Canada represents the expansion of an existing strategic collaboration between the companies. We already have commercial rights to Seres’ investigational treatments for CDI and inflammatory bowel disease outside of the US and Canada, and with this expansion, Nestlé Health Science becomes Seres’ global collaborator in SER-109.
Choose partners
Image
Seres_Therapeutics_logo